



4 March 2025

Medicine Supply Alert Notice

Triptorelin acetate (Gonapeptyl® Depot) 3.75mg powder and solvent for suspension for injection pre-filled syringes

Priority: Level 2*

Valid until: early January 2026

Issue

1. Triptorelin acetate (Gonapeptyl Depot®) 3.75mg powder and solvent for suspension for injection pre-filled syringes will be out of stock from early March 2025 until early January 2026.
2. Alternative gonadotrophin-releasing hormone (GnRH) analogues remain available.

Advice and Actions

3. Prescribers should:

- not initiate new patients on triptorelin acetate (Gonapeptyl Depot®) 3.75mg powder and solvent for suspension for injection pre-filled syringes until the shortage has resolved;
- consider prescribing alternative GnRH analogues (see Additional information section below). Primary care prescribers may wish to consult specialist teams when considering an alternative GnRH analogue. Individual summary of product characteristics (SmPCs) should be checked for indications, dosing, administration, contraindications, cautions and excipients as these vary. All prescribers should ensure that the person:
 - is not intolerant to any of the excipients;
 - is counselled on the dose frequency of the new product;
 - receives appropriate training on the administration of the new product and is counselled on the appropriate dose and volume to administer if self-administering;
 - is signposted to online training videos if needed;
 - is provided with the appropriate ancillaries and a sharps bin for safe disposal of needles.
- if the above options are not considered appropriate, or primary care prescribers require specialist input, advice should be sought from specialists on management options.

Additional Information

Clinical Information

*<https://www.nss.nhs.scot/media/1842/medicine-supply-alert-notice-definitions-of-classifications-21-october-2019.pdf>

4. Triptorelin acetate (Gonapeptyl Depot®) 3.75mg powder and solvent for suspension for injection pre-filled syringes are licensed for:
- the treatment of hormone dependent locally advanced or metastatic prostate cancer (administered every 4 weeks);
 - symptomatic endometriosis confirmed by laparoscopy when suppression of the ovarian hormonogenesis is indicated to the extent that surgical therapy is not primarily indicated (administered every 4 weeks); and
 - treatment of confirmed central precocious puberty [girls under 9 years, boys under 10 years] (dosing frequency can vary depending on response).

Table 1: The table below details available parenteral GnRH analogues approved for indications covered by triptorelin acetate (Gonapeptyl Depot®) 3.75mg powder and solvent for suspension for injection pre-filled syringes.

Agent	Brand	Presentation	Indication	Usual dose frequency
Goserelin	Zoladex® 3.6mg	Implant	Prostate cancer, endometriosis and uterine fibroids	28 days
	Zoladex® LA 10.8mg	Implant	Prostate cancer	12 weeks
Leuprorelin acetate	PROSTAP® PD DCS 1.88mg powder and solvent for prolonged-release suspension for injection	Pre-filled syringe	Precocious puberty	One month
	PROSTAP® SR DCS 3.75mg powder and solvent for prolonged-release suspension for injection	Pre-filled syringe	Prostate cancer, precocious puberty, endometriosis and uterine fibroids	One month
	PROSTAP® 3 DCS 11.25mg powder and solvent for prolonged-release suspension for injection	Pre-filled syringe	Prostate cancer, precocious puberty and endometriosis	Three months
	Staladex® 11.25mg	Implant	Prostate cancer	Three months
Triptorelin acetate	Decapeptyl® SR 3mg powder and solvent for suspension for injection	Powder and solvent	Prostate cancer, endometriosis and uterine fibroids	28 days
Triptorelin pamoate	Decapeptyl® SR 11.25mg powder and solvent for suspension for injection	Powder and solvent	Prostate cancer, precocious puberty and endometriosis	Three months
	Decapeptyl® SR 22.5mg powder and solvent for suspension for injection	Powder and solvent	Prostate cancer and precocious puberty	Six months

Specialist Pharmacy Service (SPS) website

5. The UK Department of Health and Social Care (DHSC) in conjunction with the Specialist Pharmacy Service (SPS) have launched an online Medicines Supply Tool, which provides up to date information about medicine supply issues. To access the online Medicines Supply Tool you need to register with the [SPS website](#). Registration for access to the website is available to UK healthcare professionals and organisations providing NHS healthcare. The tool is located under the Tools tab and then click on the Medicines Supply option.
6. We encourage prescribers, pharmacy professionals, and pharmacy procurement leads in Scotland to register with the SPS website and use its Medicine Supply Tool to stay up to date concerning medicines supply disruptions. Please be aware that while medicines supply issues will appear on the SPS website, some of the recommended actions may not always be appropriate / relevant within the Scottish context.

Enquiries

7. Enquiries from Health Boards or healthcare professionals should be directed in the first instance to PharmacyTeam@gov.scot (primary care) or NSS.NHSSMedicineShortages@nhs.scot (secondary care).

